New changes in drug retailing are on the way

Two-ticket system, quality and efficacy consistency evaluation of generic drugs, reform of public hospitals, adjustment of medical insurance catalogue, hierarchical management of drugstores, reform of drug regulatory system and institutional reform...In 2018, these "hot words" constantly talked about by people in the drug retail industry reflect the strong correlation between the drug retail industry and the new medical reform, drug regulation and other policies.

The new health reform has spawned six big changes

The pharmaceutical retail industry is at the beginning of a new revolution.From the upper level, new policies on medical reform and drug regulation have been introduced, the medical and health service system and the national health service system have been improved, and people's health needs have been further released.From the perspective of industrial trend, the market environment is undergoing drastic changes, and pharmaceutical separation and new retail development have become the mainstream trend.From the perspective of market trend, consumers have changed their decision to purchase drugs, diversified and personalized their health needs, and paid more attention to drug quality and brand.

It is reported that in 2017, the total scale of China's drug market (excluding retail medicinal materials) reached RMB 1580 billion, 6.0% higher than that of 2016, and the compound growth rate was 7.5% in five years.Experts predict that China's drug market will reach 1712 billion yuan in 2018, an increase of 8.3 percent over 2017.Affected by the full implementation of zero-margin drug sales and the negotiation of medical insurance prices, drug prices are facing downward pressure.

Since 2017, under the influence of the new medical reform policy, the drug terminal market has undergone six changes.

First, drug sales growth in grade hospitals slowed down.By September 2017, China's public hospitals have implemented zero-margin drug sales, resulting in only 1.5% and 3.4% year-on-year growth of drug use in urban and county-level hospitals in 2017.Restrictions on the proportion of drugs, charges per disease type, and deepening the reform of medical insurance payment all have an impact on the drug sales of grade hospitals, with the sales shares of large infusion, auxiliary drugs and traditional Chinese medicine injections declining.Among the major proprietary Chinese medicine injections, the sales of heart disease treatment drugs, anti-tumor drugs, cough and cold drugs showed a negative growth in 2017, with cough and cold drugs dropping by nearly 10%.

Second, the use of drugs in primary medical institutions is growing rapidly.In 2017, the scale of drug use in urban primary hospitals reached 95.1 billion yuan, an increase of 8.9% year-on-year and a compound growth rate of 16.0%.The scale of drug use in rural primary hospitals reached 71.2 billion yuan, up 3.8% year on year, and the compound growth rate was 7.2%.The increase of drug use in primary medical institutions is mainly due to the initial results of hierarchical diagnosis and treatment measures, and the gradual lifting of restrictions on primary drug use in various provinces.

Other Dynamics

Mitiglinide Calcium Capsules The new version of the medical insurance catalog of clinical application advantages of analysis

Early-phase insulin secretion defect is a characteristic manifestation of abnormal insulin secretion pattern in type 2 diabetes mellitus patients, and insulinotropic agents have an important role in the treatment of type 2 diabetes mellitus. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the national health insurance catalog, Diabetes International invited Prof. Mou Yiming of the General Hospital of the Chinese People's Liberation Army to explain the advantages of the application and the applicable population of Miglinide calcium, and to analyze the benefits that will be provided to the patients after its entry into the health insurance.

Explanation of pharmacological effects of Miglinide calcium in the new version of the medical insurance catalog

Defective β-cell insulin secretion is one of the central aspects of the pathogenesis of type 2 diabetes. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the National Health Insurance Catalog, Diabetes International invited Prof. Zhigang Zhao of the Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, to make a professional analysis of the advantages of the action of the new insulinotropic agent from the perspective of pharmacology.

Effective reduction of postprandial hyperglycemia preferred medication - Miglinide calcium capsule

What's worse, the probability of diabetes is increasing among people under the age of 40, as well as pregnant women, and even primary and secondary school students in China.

Golden single product, the heart and brain with treatment - Yixinone dispersible tablets

According to the World Health Organization: the number of people suffering from cardiovascular disease in China has reached 300 million, i.e. 2 out of every 10 adults suffer from cardiovascular disease.

Pioglitazone is the preferred drug for the treatment of type 2 diabetes mellitus.

Diabetes mellitus is a disorder of sugar, fat and protein metabolism caused by a defect in insulin secretion or a decrease in the sensitivity of body tissues and cells to insulin. It is characterized by high blood glucose and is often characterized by excessive urination, drinking, eating and wasting, i.e. "three more and one less".

Drug procurement "national first standard" came drug companies or face different situations

On November 15, the full text of the "4+7" Cities Drug Centralized Purchasing Document was published. With the consent of the Central Committee for Comprehensively Deepening Reform, the State organized a pilot centralized procurement of medicines, and the scope of the pilot area is Beijing, Tianjin, Shanghai, Chongqing, as well as Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, Xi'an, and other 11 cities (referred to as the "4 + 7 cities"). According to the procurement documents, the first batch of banded procurement catalog totaled 31 varieties, including cefuroxime tablets, escitalopram oxalate tablets, and resuvastatin calcium tablets that have been full of three enterprises through consistency evaluation.